A number of immune checkpoint inhibitors (ICIs), including antibodies targeting programmed death protein‐1 (PD‐1) and its ligand (PD‐L1), as well as antibodies against cytotoxic T‐lymphocyte‐associated protein 4 (CTLA‐4), have received approval for the treatment of HCC [15, 17]. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.